ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 68 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 38.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $22,000 | -8.3% | 62,846 | +15.8% | 0.00% | – |
| Q1 2017 | $24,000 | +33.3% | 54,248 | +51.8% | 0.00% | – |
| Q4 2016 | $18,000 | -5.3% | 35,744 | -3.1% | 0.00% | – |
| Q3 2016 | $19,000 | -55.8% | 36,873 | -14.7% | 0.00% | – |
| Q2 2016 | $43,000 | +43.3% | 43,206 | 0.0% | 0.00% | – |
| Q1 2016 | $30,000 | -42.3% | 43,206 | 0.0% | 0.00% | – |
| Q4 2015 | $52,000 | -45.8% | 43,206 | -0.1% | 0.00% | – |
| Q3 2015 | $96,000 | +118.2% | 43,234 | +129.4% | 0.00% | – |
| Q2 2015 | $44,000 | +18.9% | 18,846 | +10.0% | 0.00% | – |
| Q1 2015 | $37,000 | -5.1% | 17,133 | 0.0% | 0.00% | – |
| Q4 2014 | $39,000 | -15.2% | 17,133 | +0.0% | 0.00% | – |
| Q3 2014 | $46,000 | -64.1% | 17,132 | -50.0% | 0.00% | – |
| Q2 2014 | $128,000 | -83.0% | 34,264 | -46.7% | 0.00% | – |
| Q1 2014 | $755,000 | +45.2% | 64,226 | +2.9% | 0.00% | – |
| Q4 2013 | $520,000 | -53.7% | 62,425 | -48.5% | 0.00% | – |
| Q3 2013 | $1,124,000 | +89.2% | 121,214 | +100.0% | 0.00% | – |
| Q2 2013 | $594,000 | – | 60,620 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 603,740 | $5,917,000 | 4.55% |
| TANG CAPITAL MANAGEMENT LLC | 933,100 | $9,144,000 | 3.60% |
| JAY JEFFREY R | 347,004 | $3,401,000 | 2.69% |
| RA Capital Management | 863,332 | $8,461,000 | 1.12% |
| QVT Financial LP | 400,000 | $3,920,000 | 0.26% |
| SABBY MANAGEMENT, LLC | 396,730 | $3,888,000 | 0.26% |
| J. Goldman & Co LP | 222,907 | $2,184,000 | 0.22% |
| J. Goldman & Co LP | 156,000 | $1,529,000 | 0.16% |
| Tekla Capital Management LLC | 113,100 | $1,108,000 | 0.15% |
| Visium Asset Management, LP | 445,698 | $4,368,000 | 0.10% |